|
1 |
Time to Loss of Disease Control following Guselkumab Withdrawal in Relation to Initial Speed of Response: A post hoc Analysis of the VOYAGE 2 Trial
Enthalten in Dermatology Bd. 241, 2025, Nr. 2: 133-142. 10 S.
|
|
|
|
2 |
Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis
Enthalten in International archives of allergy and immunology Bd. 186, 2025, Nr. 7: 670-677. 8 S.
|
|
|
|
3 |
Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of Azelastine Hydrochloride in Children with Perennial Allergic Rhinitis
Enthalten in International archives of allergy and immunology Bd. 186, 2025, Nr. 7: 670-677. 8 S.
|
|
|
|
4 |
Bronchiektasen-Erkrankung
Enthalten in Deutsche medizinische Wochenschrift Bd. 150, 2025, Nr. 12: 703-712
|
|
|
|
5 |
Update Raynaud-Syndrom
Enthalten in Deutsche medizinische Wochenschrift Bd. 150, 2025, Nr. 12: 661-667
|
|
|
|
6 |
Does Improvement of Glycemic Control Cause Acute Charcot Foot in Patients with Diabetes?
Enthalten in Experimental and clinical endocrinology & diabetes Bd. 133, 2025, Nr. 03: 120-132
|
|
|
|
7 |
The Role of Infant Gut Microbiota Modulation by Perinatal Maternal Probiotic Intervention in Atopic Eczema Risk Reduction
Enthalten in Neonatology Bd. 122, 2025, Nr. 1: 84-94. 11 S.
|
|
|
|
8 |
Adjuvant Therapy with Pembrolizumab in Renal Cell Carcinoma: Real-World Experiences from a Retrospective, Multi-Institutional Cohort
Enthalten in Urologia internationalis Bd. 109, 2025, Nr. 3: 291-298. 8 S.
|
|
|
|
9 |
Preliminary Efficacy, Tolerability, and Safety Analysis of Darolutamide for Metastatic Castration-Resistant Prostate Cancer: A Single-Center, Open-Label Study
Enthalten in Urologia internationalis Bd. 109, 2025, Nr. 2: 167-174. 8 S.
|
|
|
|
10 |
Unterschiedlich ausgeprägte Placebo-Effekte bei psychischen Erkrankungen
Enthalten in Fortschritte der Neurologie, Psychiatrie Bd. 93, 2025, Nr. 04: 119-119
|
|
Administration
